2023 World Conference on Lung Cancer (Posters)-EP06.02. Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective

EP06.02. Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective - PDF(Abstract)

Back to course

Pdf Summary

In this study, the prevalence of PD-L1 expression in non-small cell lung cancer (NSCLC) patients was investigated in a real-world Australian setting. PD-L1 is a protein that inhibits cytotoxic T cell responses in the immune system and is targeted by immune checkpoint inhibitors. The study collected diagnostic reports and associated data from pathology service laboratories for NSCLC patients diagnosed between 2018 and 2020.<br /><br />The results showed that PD-L1 expression rates varied based on clinico-pathologic features. Tumour proportion scores (TPS) of 1% were more common in squamous cell carcinoma compared to other histologies. Women had slightly higher TPS scores of 1% compared to men. There was no difference in PD-L1 expression based on age groups. Stage III/IV specimens had slightly higher scores of 1% or 50% compared to stage I/II samples. Metastatic samples had slightly higher TPS scores of 50% compared to primary samples.<br /><br />Cytology and biopsy samples had similar rates of PD-L1 expression scores of 1%, but cytology samples had slightly higher rates of 50% scores compared to biopsy samples. Resection specimens had lower rates of TPS 50% or 1% compared to biopsy and cytology samples. There were no differences in PD-L1 expression based on the assay platforms used.<br /><br />The study concluded that there were significant relationships between PD-L1 expression scores and histologic type, specimen types, sites, and stage in NSCLC patients. However, there were no differences based on age group or sex. The findings of this study were consistent with other published real-world studies.<br /><br />Overall, the study provides insights into the prevalence of PD-L1 expression in NSCLC patients in Australia and its correlation with various clinico-pathologic features. These findings contribute to the understanding of biomarkers for immuno-oncology, specifically in the context of PD-L1 expression in NSCLC.

Asset Subtitle

Sarita Prabhakaran

Meta Tag

Speaker Sarita Prabhakaran

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

PD-L1 expression

non-small cell lung cancer

NSCLC

Australian setting

cytotoxic T cell responses

immune checkpoint inhibitors

tumour proportion scores

squamous cell carcinoma

metastatic samples

biopsy samples